Report with the AI impact on market trends- The global ursodeoxycholic acid market size is estimated to grow by USD 463.2 ...

The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for ...

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

In patients with chronic liver disease, including PBC, ursodeoxycholic acid shows promise as an adjunctive therapy for COVID-19 infection.

In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) ...

GI and liver disease in pregnancy should be managed with preconception and contraceptive counseling, coordination of birth, ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in ...

Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes includes anticholestatic therapy with ursodeoxycholic acid and immunosuppressive therapy with corticosteroids and azathioprine.

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibran ...

Report on how AI is redefining market landscape- The global amniotic membrane market size is estimated to grow by USD 2.7 billion from 2024-2028, according to Technavio. The market is estimated to ...